Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Genespire Glides Into Gene Therapy Space

Sofinnova Partners Invests In Italian Biotech

Executive Summary

Milan, Italy is a hotspot in Europe for gene therapy research, and the European VC Sofinnova Partners is backing the latest start-up aimed at metabolic and primary immunodeficiencies.

You may also be interested in...



The Future Of Medicine: Cell And Gene Therapies Take The Lead

BIO panel with Roche’s James Sabry, Spark’s Federico Mingozzi and Adaptive’s Harlan Robins imagines a world where cell and gene therapies are preferred over small molecules and antibodies.

Orchard Plans EU Submission For GSK-Originated MLD Gene Therapy

Orchard is aiming to get its second autologous gene therapy on the market next year, with a European filing for MLD and a BLA to follow.

GSK Investigates 'Different Pricing Options' Following CHMP Nod For 'Bubble Boy' Gene Therapy

GlaxoSmithKline PLC's 'bubble boy' treatment has been given a positive opinion by the European Medicines Agency's advisory committee.

Topics

Related Companies

UsernamePublicRestriction

Register

SC142140

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel